Serum metabolomic signatures of cutaneous malignancies identified by untargeted profiling
Medicine and Pharmacy Reports · 02.04.2026
DOI: 10.15386/mpr-2960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine and Pharmacy Reports, online erschienen am 02.04.2026. Verfasst von Amalia Moisoiu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, County Emergency Clinical Hospital, Cluj-Napoca, Romania. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and aims. Skin cancers are among the most common malignancies worldwide, and improved non-invasive diagnostic tools are needed to support clinical decision making. Metabolomics offers a promising approach by capturing systemic biochemical alterations associated with tumor presence.
Methods
In this study, we performed untargeted serum metabolomic profiling based on high-performance liquid chromatography coupled with mass spectrometry in 85 individuals, including 49 with basal cell carcinoma, 19 with squamous cell carcinoma, 8 with melanoma and 9 with benign lesions.
Results
The analysis yielded 98 polar metabolites and 53 lipophilic metabolites that passed quality filtering. Thirteen metabolites showed significant differences between the cancer and benign groups, including lysophosphatidylcholine (20:3), N-palmitoyl tryptophan, serotonin, and fumaric acid. Principal component analysis demonstrated clear separation between malignant and benign groups, while cancer samples displayed wider metabolic variability consistent with tumor heterogeneity. Integrating principal component scores into a linear discriminant model yielded an area under the ROC curve of 0.98 corresponding to a sensitivity of 96% and a specificity of 67%. Pathway enrichment analysis revealed consistent alterations in mitochondrial electron transport, amino acid metabolism, the urea cycle, and the Warburg effect, indicating that common metabolic pathways are perturbed across cutaneous malignancies.
Conclusions
These findings show that serum metabolomics can distinguish cancer from benign skin lesions and highlight metabolic signatures that may serve as potential biomarkers for non-invasive assessment of skin cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, County Emergency Clinical Hospital, Cluj-Napoca, Romania.
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania.
- Interservisan Medical-Surgical Center, Cluj-Napoca, Romania.
- Center for Applied Biotechnology Biodiatech, S.C. Proplanta S.R.L., Cluj-Napoca, Romania.
- 2 Internal Medicine Department, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.
Zitieren
APA
Moisoiu, A., Moisoiu, T., Bocşa, C., Socaciu, C., & Fodor, D. (2026). Serum metabolomic signatures of cutaneous malignancies identified by untargeted profiling. Medicine and Pharmacy Reports. https://doi.org/10.15386/mpr-2960
Vancouver
Moisoiu A, Moisoiu T, Bocşa C, Socaciu C, Fodor D. Serum metabolomic signatures of cutaneous malignancies identified by untargeted profiling. Medicine and Pharmacy Reports. 2026. doi:10.15386/mpr-2960
BibTeX
@article{Moisoiu2026,
author = {Moisoiu, Amalia and Moisoiu, Tudor and Bocşa, Corina and Socaciu, Carmen and Fodor, Daniela},
title = {Serum metabolomic signatures of cutaneous malignancies identified by untargeted profiling},
journal = {Medicine and Pharmacy Reports},
year = {2026},
doi = {10.15386/mpr-2960}
}
EUVIMED